Related Experiment Video
Updated: Jun 3, 2026
03:48
Mouse Bladder Wall Injection
Published on: July 12, 2011
IL-23 gene therapy for mouse bladder tumour cell lines
Tomomi Kuramoto1, Reona Fujii, Hiroshi Nagai
1Department of Urology, Wakayama Medical University, Wakayama, Japan. kurapon@wakayama-med.ac.jp
BJU International
|March 26, 2011
Summary
Interleukin-23 (IL-23) gene transfer into mouse bladder carcinoma (MBT2) cells induced rejection and a vaccine effect against tumors. CD8 T cells mediated this antitumor response, enhanced by CD25 depletion.
Area of Science:
- Immunology
- Cancer Biology
- Gene Therapy
Background:
- Interleukin-23 (IL-23) is a cytokine involved in immune responses.
- Gene transfer offers a potential strategy for cancer therapy.
Purpose of the Study:
- To evaluate the antitumor effects of IL-23 gene transfer into mouse bladder carcinoma (MBT2) cells.
- To investigate the mechanisms of IL-23 secretion and its impact on tumor immunity.
Main Methods:
- Liposome-mediated gene transfer was used to introduce the IL-23 gene into MBT2 cells.
- In vivo studies involved injecting IL-23-secreting MBT2 cells (MBT2/IL-23) into syngeneic mice and conducting tumor vaccination experiments.
- Mechanisms were explored via antibody depletion of immune cells (CD8, CD4, NK) and immunohistochemistry.
Main Results:
- MBT2/IL-23 cells stably secreted IL-23 and were rejected in syngeneic mice.
- Vaccination with mitomycin C (MMC)-treated MBT2/IL-23 inhibited parental MBT2 tumor growth at a distant site.
- CD8 T cells were identified as the primary effector cells mediating the direct antitumor effect.
Conclusions:
- IL-23-secreting MBT2 cells induce rejection through CD8 T cell activation.
- Genetically modified MBT2/IL-23 cells serve as a potential tumor vaccine, with enhanced efficacy when combined with CD25 depletion.
